Biotech Values

[ThomasS]

VRTX: "Are these results good enough for the FDA to approve Telaprevir in the second-line setting without waiting for data from phase-3? If it were up to me, the answer would be Yes, but I have no idea what the FDA will actually do."

A possible reason they may not: Doctors would prescribe the regime for treatment-naive patients, already knowing the efficacy blasts SoC.